March 15, 2011

Cardiovascular and Renal Outcomes With Telmisartan, Ramipril, or Both in People at High Renal Risk: Results From the ONTARGET and TRANSCEND Studies.

.   .   

This post hoc analysis examines the renal subgroups in the studies ONTARGET and TRANSCEND. The results do not support dual therapy over monotherapy in high-vascular risk patients with low glomerular filtration rate or albuminuria.

Related Articles:

Chronic Kidney Disease, RAS Blockade

Comments are closed.